ZYME vs. PTGX, AAPG, SRRK, MTSR, KYMR, VKTX, MOR, CRNX, ALVO, and MLTX
Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), Metsera (MTSR), Kymera Therapeutics (KYMR), Viking Therapeutics (VKTX), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.
Zymeworks vs. Its Competitors
Protagonist Therapeutics (NASDAQ:PTGX) and Zymeworks (NYSE:ZYME) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.
98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 4.9% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 1.9% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Protagonist Therapeutics has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Protagonist Therapeutics had 2 more articles in the media than Zymeworks. MarketBeat recorded 5 mentions for Protagonist Therapeutics and 3 mentions for Zymeworks. Protagonist Therapeutics' average media sentiment score of 0.54 beat Zymeworks' score of 0.20 indicating that Protagonist Therapeutics is being referred to more favorably in the media.
Protagonist Therapeutics has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.
Protagonist Therapeutics has a net margin of 27.04% compared to Zymeworks' net margin of -182.75%. Protagonist Therapeutics' return on equity of 9.22% beat Zymeworks' return on equity.
Protagonist Therapeutics currently has a consensus price target of $66.10, indicating a potential upside of 29.10%. Zymeworks has a consensus price target of $21.00, indicating a potential upside of 63.62%. Given Zymeworks' higher probable upside, analysts clearly believe Zymeworks is more favorable than Protagonist Therapeutics.
Summary
Protagonist Therapeutics beats Zymeworks on 14 of the 16 factors compared between the two stocks.
Get Zymeworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zymeworks Competitors List
Related Companies and Tools
This page (NYSE:ZYME) was last updated on 7/5/2025 by MarketBeat.com Staff
